Literature DB >> 24222093

HCV and host lipids: an intimate connection.

Esperance A K Schaefer1, Raymond T Chung.   

Abstract

The hepatitis C virus (HCV) requires elements of host lipid metabolism for every step in the viral life cycle. Clinically, it has long been observed that patients with chronic hepatitis C have lower nonhigh-density lipoprotein cholesterol, and these levels rise after successful treatment. The HCV itself circulates as a highly lipidated lipoviral particle, which closely resembles very low-density lipoprotein (VLDL). Several required coentry factors for the virus to gain access to the hepatocytes have been described, and several, including SRB1, LDL-R, and the NPC1L1 receptors, are important receptors for lipoprotein and cholesterol uptake. Inside the cell, the virus induces lipogenesis, and specifically induces the master regulator sterol response element binding protein. Viral replication then requires the concerted efforts of viral proteins combined with several host factors involved in cholesterol synthesis. The virus is then packaged alongside the cellular machinery for VLDL production. The complex interplay highlights pathways of hepatic steatosis and unveils drug targets for the treatment of HCV. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24222093     DOI: 10.1055/s-0033-1358524

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  28 in total

1.  Increased hepatic expression of miRNA-122 in patients infected with HCV genotype 3.

Authors:  Ketti G Oliveira; Fernanda M Malta; Ana C S S Nastri; Azzo Widman; Paola L Faria; Rúbia A F Santana; Venâncio A F Alves; Flair J Carrilho; João R R Pinho
Journal:  Med Microbiol Immunol       Date:  2015-08-14       Impact factor: 3.402

2.  Therapy. Statins and liver disease: from concern to 'wonder' drugs?

Authors:  Jaume Bosch; Xavier Forns
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-05-12       Impact factor: 46.802

Review 3.  Viral activation of cellular metabolism.

Authors:  Erica L Sanchez; Michael Lagunoff
Journal:  Virology       Date:  2015-03-23       Impact factor: 3.616

Review 4.  Hepatitis C virus relies on lipoproteins for its life cycle.

Authors:  Germana Grassi; Giorgia Di Caprio; Gian Maria Fimia; Giuseppe Ippolito; Marco Tripodi; Tonino Alonzi
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

5.  Oxidative Stress Attenuates Lipid Synthesis and Increases Mitochondrial Fatty Acid Oxidation in Hepatoma Cells Infected with Hepatitis C Virus.

Authors:  Donna N Douglas; Christopher Hao Pu; Jamie T Lewis; Rakesh Bhat; Anwar Anwar-Mohamed; Michael Logan; Garry Lund; William R Addison; Richard Lehner; Norman M Kneteman
Journal:  J Biol Chem       Date:  2015-12-01       Impact factor: 5.157

Review 6.  Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients.

Authors:  Roger Bedimo; Oladapo Abodunde
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

7.  Infection of Hepatocytes With HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Up-regulating SMAD6 and SMAD7.

Authors:  Fang Zhang; Catherine Sodroski; Helen Cha; Qisheng Li; T Jake Liang
Journal:  Gastroenterology       Date:  2016-09-30       Impact factor: 22.682

Review 8.  Interaction of pathogens with host cholesterol metabolism.

Authors:  Dmitri Sviridov; Michael Bukrinsky
Journal:  Curr Opin Lipidol       Date:  2014-10       Impact factor: 4.776

Review 9.  Immunologic, metabolic and genetic factors in hepatitis C virus infection.

Authors:  Nora A Fierro; Karina Gonzalez-Aldaco; Rafael Torres-Valadez; Erika Martinez-Lopez; Sonia Roman; Arturo Panduro
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

10.  Metabolic Syndrome in HIV/HCV Co-infected Patients.

Authors:  Lauren F Collins; Ruth O Adekunle; Emily J Cartwright
Journal:  Curr Treat Options Infect Dis       Date:  2019-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.